留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

绝经激素治疗增加乳腺癌患病风险:Lancet最新文献解读

徐颖 徐雅莉 王喆 林燕 王常珺 孙强

徐颖, 徐雅莉, 王喆, 林燕, 王常珺, 孙强. 绝经激素治疗增加乳腺癌患病风险:Lancet最新文献解读[J]. 协和医学杂志, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
引用本文: 徐颖, 徐雅莉, 王喆, 林燕, 王常珺, 孙强. 绝经激素治疗增加乳腺癌患病风险:Lancet最新文献解读[J]. 协和医学杂志, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020
Citation: Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. doi: 10.3969/j.issn.1674-9081.2020.05.020

绝经激素治疗增加乳腺癌患病风险:Lancet最新文献解读

doi: 10.3969/j.issn.1674-9081.2020.05.020
详细信息
    通讯作者:

    孙强 电话: 010-69152700,E-mail: sunqiang@163.com

  • 中图分类号: R737.9

Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019

More Information
  • 摘要: 绝经激素治疗(menopausal hormone therapy, MHT)是否会增加乳腺癌的发病风险一直存在争议。2019年9月,Lancet发表了一篇荟萃分析,汇集了世界范围内关于MHT与乳腺癌发病风险的证据。此研究结果表明,除阴道应用雌激素外,所有方式应用MHT均增加乳腺癌发病风险,且该风险随MHT应用时间的延长逐渐升高。其中雌激素、孕激素联合治疗风险更高,停药后额外风险可持续10年以上。小剂量应用MHT或选择天然孕激素等并不能回避乳腺癌发病风险的增加。本文对该荟萃分析进行解读,强调应用MHT需考虑乳腺癌风险,全面评估患者风险与获益。
    利益冲突  无
  • [1] Lindsey A, Freddie Bray T, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65:87-108. doi:  10.3322/caac.21262
    [2] Parkin DM, Boyd L, Walker LC. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010[J]. Br J Cancer, 2011, 105:S77-S81. doi:  10.1038/bjc.2011.489
    [3] Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288:321-333. doi:  10.1001/jama.288.3.321
    [4] Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial[J]. JAMA, 2003, 289:3243-3253. doi:  10.1001/jama.289.24.3243
    [5] Beral V, Reeves G, Bull D, et al. Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy[J]. J Natl Cancer Inst, 2011, 103:296-305. doi:  10.1093/jnci/djq527
    [6] Stahlberg C, Pedersen AT, Andersen ZJ, et al. Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy[J]. Br J Cancer, 2004, 91:644-650. doi:  10.1038/sj.bjc.6601996
    [7] Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort[J]. Int J cancer, 2005, 114:448-454. doi:  10.1002/ijc.20710
    [8] Roman M, Sakshaug S, Graff-Iversen S, et al. Postmenopausal hormone therapy and the risk of breast cancer in Norway[J]. Int J Cancer, 2016, 138:584-593. doi:  10.1002/ijc.29810
    [9] Jones ME, Schoemaker MJ, Wright L, et al. Menopausal hormone therapy and breast cancer: what is the true size of the increased risk?[J].Br J Cancer, 2016, 115:607-615. doi:  10.1038/bjc.2016.231
    [10] Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials[J]. JAMA Oncol, 2015, 1:296-305. doi:  10.1001/jamaoncol.2015.0494
    [11] Thorbjarnardottir T, Olafsdottir EJ, Valdimarsdottir UA, et al. hormone replacement therapy and breast cancer risk: A cohort study of 16 928 women 48 years and older[J]. Acta Oncol, 2014, 53:752-758. doi:  10.3109/0284186X.2013.878471
    [12] Fournier A, Mesrine S, Dossus L, et al. Risk of breast cancer after stopping menopausal hormone therapy in the E3N cohort. Breast Cancer Research and Treatment[J]. Breast Cancer Res Treat, 2014, 145:535-543. doi:  10.1007/s10549-014-2934-6
    [13] Pizot C, Boniol M, Mullie P, et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies[J]. Eur J Cancer, 2016, 52:138-154. doi:  10.1016/j.ejca.2015.10.063
    [14] Reeves GK, Beral V, Green J, et al. Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis[J]. Lancet Oncol, 2006, 7:910-918. doi:  10.1016/S1470-2045(06)70911-1
    [15] Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials[J]. Hum Reprod Update, 2005, 11:561-573. doi:  10.1093/humupd/dmi031
    [16] Manson JE, Chlebowski RT, Stefanick ML, et al. The Women's Health Initiative Hormone Therapy Trials: Update and Overview of Health Outcomes During the Intervention and Post-Stopping Phases[J]. JAMA, 2013, 301:1353-1368. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/0148607102026001011
    [17] Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women[J].N Engl J Med, 2008, 14, 359: 697-708. doi:  10.1097/01.ogx.0000338097.79940.0c
    [18] Chlebowski RT, Anderson GL, Aragaki AK, et al.Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index[J]. J Nat Cancer Inst, 2016;108. http://www.ncbi.nlm.nih.gov/pubmed/26546117
    [19] Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394:1159-1168. doi:  10.1016/S0140-6736(19)31709-X
    [20] Munsell MF, Sprague BL, Berry DA, et al. Body Mass Index and Breast Cancer Risk According to Postmenopausal Estrogen- Progestin Use and Hormone Receptor Status[J]. Epidemiol Rev, 2014, 36:114-136. doi:  10.1093/epirev/mxt010
    [21] Wang K, Li F, Chen L, et al.Change in risk of breast cancer after receiving hormone replacement therapy by considering effect-modifiers: a systematic review and dose-response meta-analysis of prospective studies[J].Oncotarget, 2017, 8:81109-81124. doi:  10.18632/oncotarget.20154
    [22] Maas P, Barrdahl M, Joshi AD, et al. Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States[J]. JAMA Oncol, 2016, 2:1295-1302. doi:  10.1001/jamaoncol.2016.1025
    [23] 徐颖, 林燕, 王常珺, 等.共识与争议:绝经激素治疗与乳腺癌发病风险[J].协和医学杂志, 2018, 9:332-335. https://mjpumch.cbpt.cnki.net/WKC3/WebPublication/paperDigest.aspx?paperID=d455fd28-6dbd-4caf-abc7-c61a7faf1ebc

    Xu Y, Lin Y, Wang CJ, et al. Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma[J]. Med J PUMCH, 2018, 9:332-335. https://mjpumch.cbpt.cnki.net/WKC3/WebPublication/paperDigest.aspx?paperID=d455fd28-6dbd-4caf-abc7-c61a7faf1ebc
    [24] Saxena T, Lee E, Henderson KD, et al.Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19:2366-2378. doi:  10.1158/1055-9965.EPI-10-0162
    [25] Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: An overestimated risk?[J]. Eur J Cancer, 2017, 84:60-68. doi:  10.1016/j.ejca.2017.07.012
    [26] Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study[J].Lancet, 2003, 362: 419-427. doi:  10.1016/S0140-6736(03)14065-2
    [27] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol 2014, 15:e279-e289. doi:  10.1016/S1470-2045(13)70567-9
    [28] LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a random-ized controlled trial[J]. JAMA, 2011, 305:1305-1314. doi:  10.1001/jama.2011.382
  • 加载中
计量
  • 文章访问数:  74
  • HTML全文浏览量:  12
  • PDF下载量:  22
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-11-18
  • 刊出日期:  2020-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!